The development of a 'two-site' immunoradiometric assay (i.r.m.a.) for the direct estimation of human corticotropin-(l-39)-peptide in plasma is described. The assay is based on the simultaneous addition of 125I-labelled sheep anti-(N-terminal corticotropin) IgG (immunoglobulin G) antibodies and rabbit anti-(C-terminal corticotropin) antiserum to standards and unknowns (0.5ml) followed by 18h incubation. The use of solid-phase reagents was avoided in order to minimize non-specific effects and the time required for reactants to reach equilibrium. Instead, the separation of corticotropin-bound from free labelled antibody is achieved by the addition of sheep anti-(rabbit IgG) antiserum, which precipitates bound labelled antibody by complexformation with rabbit anti-corticotropin antibodies, which are also hormone-bound. Several 1251-labelled sheep anti-(N-terminal corticotropin) IgG preparations were assessed in the i.r.m.a. Although each was derived from antisera raised to a thyroglobulin conjugate of synthetic corticotropin-(l-24)-peptide (Synacthen), purification of immunoglobulins before iodination by selective immunoadsorption resulted in preparations with distinct specificities which demonstrated marked differences in binding to intact human corticotropin-(1-39)-peptide. These preparations are compared in combination with two rabbit anti-(C-terminal corticotropin) antisera. A 'two-site' assay based on the use of 1251-labelled sheep anti-[corticotropin-(2-16)-peptide] IgG and rabbit anti-[corticotropin-(34-39)-peptide] antiserum was optimized, since steric inhibition of antibody binding was avoided with this combination and because the measurement of only intact human corticotropin-(l-39)-peptide and not fragments was assured by the use of terminal antibodies. This i.r.m.a. is characterized by rapid equilibration of reactants, a wide 'operating range' (the precision of dose estimates was <4% over the range 30-2200pg/ml) and high sensitivity [8pg of corticotropin/ml (95% confidence interval 3.7-12.0) (4pg minimal detectable mass) can be detected directly in plasma].
and radioreceptor (Wolfsen et al., 1972) assays, but it is the corticotropin radioimmunoassay (r.i.a. ; Yalow et al., 1964; Landon & Greenwood, 1968; Donald, 1968) which has been of the greatest use to the clinician. Nonetheless, corticotropin r.i.a.'s are not without problems. The estimation of basal circulating levels of the hormone (20-60pg/ml) by direct r.i.a. (Berson & Yalow, 1968) requires an antibody of very high affinity, and such antibodies are not readily available. Therefore, the vast majority of corticotropin r.i.a.'s employ antibodies of only moderate affinity and utilize a preliminary extraction step involving adsorption to glass powder Vol. 218 followed by elution and evaporation of solvent, to concentrate analyte from relatively large volumes of sample plasma in order to obtain the necessary assay sensitivity. However, sample extraction is a laborious procedure and subject to manipulative error and variable recoveries. A second problem has been the lack of specificity of corticotropin r.i.a.'s. Thus the cross-reaction of precursor molecules, fragments resulting from peptidase activity on the intact molecule, and other peptides with sequence homology in the r.i.a., has led to dissociation between estimates obtained by bioassay and immunoassay and difficulty in interpreting the latter (Imura et al., 1965; Fleischer et al., 1966) . Plasma peptidases present in the corticotropin fraction after extraction may also interfere directly in the r.i.a. by degrading the radioiodinated corticotropin during the long incubation periods which are characteristic of the assay. The need for a corticotropin immunoassay which overcomes the limitations of the r.i.a. has prompted us to develop an immunoradiometric assay (i.r.m.a.) for the hormone. There is increasing evidence that such assays, which are based on the use of radioisotopically labelled specific antibodies, have several practical advantages over labelled-antigen techniques. Thus they are potentially more sensitive and specific and are quicker and easier to perform (Hunter & Budd, 198 1; 198 1) . The potential of labelled-antibody immunoassays for the measurement of corticotropin has long been recognized (Addison & Hales, 1971) , but the method developed by those workers failed to demonstrate the advantages expected of it. This may be because the assay was of the conventional or 'one-site' variety and therefore subject to the limitations of that system. The assay that we have developed is of the 'two-site' variety (Wide, 1971; Addison & Hales, 1971) , except that it avoids the use of solid-phase reagents in order to reduce nonspecific effects and the time required for reacants to reach equilibrium.
We have previously reported the development of such a 'liquid-phase' i.r.m.a. for human prolactin (Hodgkinson et al., 1984) and have discussed the limitations, imposed on the performance characteristics of the assay, of using antibodies (labelled and unlabelled) which compete for binding sites on the analyte molecule. As such problems would be aggravated in assays for smaller analytes such as corticotropin, we believe that the problem would have to be overcome in order to establish a highly sensitive, clinically useful, assay for the hormone which avoids the need for sample extraction. Consequently, we have raised antibodies to extreme terminal fragments of corticotropin in order to minimize competition. This approach also has other advantages. The use of N-and C-terminally directed antibodies greatly increases assay specificity by ensuring the measurement of only the intact analyte molecule and not degradation fragments. Furthermore, addition of specific antibodies in excess ensures the rapid sequestration of analyte, removing it from the influence of plasma peptidases. The present paper discusses the development and initial validation studies of the assay.
Materials and methods

Materials
Highly purified (200i.u./mg) human corticotropin-(1-39)-peptide for use as standard was prepared in this laboratory by the method of Scott & Lowry (1974 Purification of specific immunoglobulin. Specific immunoglobulin was purified from the sheep antisera by a modification of the method of Hodgkinson & Lowry (1982) . Antiserum (lOml) was made 1.9M with respect to (NH4)2SO4 and mixed at room temperature (15min) before centrifugation (3000g, 10min). The supernatant was discarded and the precipitate resolubilized in 0.15M-NaCl (lOml) before reprecipitation as described above and resolubilization in 0.01 M-NaHCO3 containing 0.15M-NaCl and thiomersal (0.01%; 8ml).
Immunoadsorption was carried out on the resolubilized immunoglobulin fraction by mixing gently overnight with Sepharose-coupled peptide (2 ml) at 40C. The immunoadsorbent was transferred to a glass column (0.7 cm x 10 cm) and washed with 0.01 M-NaHCO3 containing 0. 15 M-NaCl and thiomersal (0.01%; lOml) and with the same buffer containing acetonitrile (20%, v/v) . Adsorbed immunoglobulin was eluted from insolubilized peptide by stepwise reduction of pH with the following buffers: 0.05M-ammonium acetate containing acetonitrile (20%, v/v) (5ml), pH6.5; 0.0675M-ammonium acetate buffer, pH5 (0.05M-ammonium acetate/0.017M-acetic acid), containing acetonitrile (20%, v/v) (5 ml); and 0.155 Mammonium acetate/formate buffer, pH 3.7 (0.05 Mammonium acetate/0. 105 M-formic acid), containing acetonitrile (20%, v/v) (5 ml). Fractions (1 ml) were collected into NH4HCO3 (1 M, 200Ml) , and the acetonitrile removed by placing eluant fractions under a stream of nitrogen. The bulk of specific immunoglobulin (1.6-1.8mg, >70%) from each of the sheep antisera was eluted at pH 3.7 in 2 x 1 ml fractions and was identified by the preparation of antiserum dilution curves and by u.v. spectrophotometry at 280nm (for IgG, A18mg/ml = 1.4). The immunoglobulin was stored at -20°C in 80,ug (0.Snmol, 80Iu) samples for radioiodination.
Sheep anti-corticotropin immunoglobulin preparation. The highly purified immunoglobulin required for radioiodination was prepared from the two sheep antisera (PSI and PS2), which were raised against the synthetic corticotropin-(1-24)-peptide (Synacthen) conjugate by using the general procedure outlined above. However, a range of immunoadsorbents were employed, which resulted in preparations with distinct specificities. Thus preparation PSi a was immunopurified on insolubilized corticotropin-(1-24)-peptide, and PSIb was immunopurified on insolubilized [D-Ser',Lys17" 8]-corticotropin-(l-1 8)-peptide amide. Antiserum PS2 did not bind to insolubilized [D-Ser',Lys17'18]-corticotropin-(1-18)-peptide amide. Instead, PS2a was prepared by immunopurification on insolubilized corticotropin-(I 1-39)-peptide.
Radioiodination of sheep anti-corticotropin immunoglobulin fractions. Radioiodination was achieved by a modification of the Iodogen method (Salacinski et al., 1981) . lodogen (100ll of a 92.5 /LM solution in dichloromethane) was added to a polypropylene vial [no. 690; Sarstedt (U.K.) Ltd., Beaumont Leys, Leicester, U.K.] and the solvent evaporated. To the vial, 0.5M-phosphate buffer, pH 7.4 (20,l), sheep anti-corticotropin IgG (80,ug, 0.5nnmol)and Na125I (lOlul, 1.OmCi, 0.5 nmol; The Radiochemical Centre, Amersham, Bucks., U.K.) were added in order. The iodination was allowed to continue for 10min before transferring the vial contents to 0.05 M-phosphate buffer, pH 7.4 (250 ul) for 5min, followed by addition of carrier sheep serum (250,l) . The incorporation of iodine into IgG ranged from 75% to 90O%, resulting in preparations with specific radioactivities between 9.4 and 11.2,uCi/,ug. The mixture was applied to a column Vol. 218
(1.0cm x 90cm) of Sephacryl S-300 previously equilibrated with 0.05 M-phosphate buffer, pH 7.4, containing bovine serum albumin (0.5%) and thiomersal (0.01%), and was eluted at 3ml -h-1. Fractions (I.5 ml) were collected. A single major peak of radioactivity was eluted in the position expected of sheep anti-corticotropin IgG (Ka,. = 0.26). To the pooled peak, mannitol (1.0%, w/v) and normal sheep serum (10%, v/v) were added before freezedrying and storage at -20°C.
The immunoreactivities of radioiodinated sheep anti-corticotropin IgG preparations were assessed by their ability to reassociate with an excess of the immunoadsorbent on which they were purified. PSi a, PS lb and PS2a each demonstrated in excess of 90% binding to their respective immunoadsorbents. Non-specific binding of labelled antibody to Sepharose 4B was less than 3%. Binding of 1251-labelled sheep anti-corticotropin IgG preparations had declined to approx. 50% after 2 months storage.
Standards. Corticotropin standards were prepared by adding a known weight of highly purified human corticotropin-(1-39y-peptide to horse serum which had previously been treated to eliminate peptidase activity. The treatment included two successive freezing and thawing cycles, heating the horse serum to 54°C for 30min, then, after cooling, addition of phenylmethanesulphonyl fluoride, phydroxymercuribenzoate, N-ethylmaleimide and EDTA, each to a final concentration of 1 mM and addition of bacitracin and thiomersal (both 0.01%). The horse serum was then mixed for 2h at room temperature and the pH adjusted to 7.4 by the dropwise addition of phosphoric acid (2M) before filtration through a 0.45 tim-pore-size filter.
Whereas a loss of immunoreactive corticotropin of 35% was observed in the untreated horse serum after 3 h incubation at 37°C, this was decreased to less than 5% in treated serum. A range of corticotropin standards from 5 to 4000pg/ml were prepared in treated horse serum and stored at -20°C in portions for assay.
I.r.m.a. development. The buffer for all assay experiments was 0.128 M-phosphate, pH 7.4 (0.104M-Na2HPO4/0.024M-NaH2PO4) containing poly(ethylene glycol) 6000 (2%, w/v), human serum albumin (0.5%, w/v), mannitol (1.0%, w/v), normal rabbit serum (1.0%, v/v), normal sheep serum (2.0%, v/v), thiomersal (0.010%) and phenylmethanesulphonyl fluoride (0.2mM).
The corticotropin i.r.m.a. avoids the use of solidphase reagents. This was achieved by using specific antibodies raised in two different species.
The radiolabelled N-terminal corticotropin antibody preparations were of sheep origin and the Cterminal-specific corticotropin antisera were raised in rabbits. The separation of corticotropin-bound from free labelled antibody could then be achieved by addition of a sheep anti-(rabbit IgG) antiserum, which precipitates bound labelled antibody by complex-formation with rabbit anti-corticotropin antibodies, which are also corticotropin-bound. (Buckler, 1971) . The general procedure for the development of the assay has previously been outlined in full (Hodgkinson et al., 1984) , with one modification, which is as follows. The amount of rabbit anti-corticotropin antiserum required to bind all of the corticotropin in the standard of highest concentration (lOOOpg/ml, 0.5ml of standard) was established by using a system analogous to an r.i.a. antiserum dilution curve. In this system, samples (0.5ml) of horse serum containing corticotropin (1000 pg/ml) andl 251-corticotropin (20000c.p.m.) were incubated with increasing dilutions of rabbit anti-corticotropin antisera in assay buffer (0.2ml, 1 : 100-1 :1000) for 24h and separated by the addition of sheep anti-(rabbit IgG) antiserum as described above. The dilution of rabbit anti-corticotropin antiserum chosen for use in the i.r.m.a. was the greatest dilution to achieve complete precipitation of the '251-corticotropin, that is, the greatest dilution of antibody that completely bound the added corticotropin. Both the rabbit anti-[corticotropin-(34-39)-peptide] antiserum (Apro) and the rabbit anti-[corticotropin-(17-39)-peptide] antiserum (CII) bound the corticotropin (500 pg) at a dilution of 1 :500.
Assay procedure. The corticotropin i.r.m.a. was of the 'simultaneous addition' variety. Standard curves were prepared by the addition of a reagent mixture (0.2ml) containing 1 25I-labelled sheep anti-corticotropin IgG (50000c.p.m./0.2ml of either PSia, PSib or PS2a) and rabbit anticorticotropin antiserum { 1:500; either anti-[corticotropin-(34-39)-peptide] (Apro) or anti-[corticotropin-(1 7-39)-peptide (CII)} in assay buffer to corticotropin standards (0-lOOOpg/ml) and unknown plasma (0.5 ml), followed by mixing and incubation overnight at room temperature. Separation of corticotropin-bound from free labelled antibody was achieved by precipitation of the bound complex using a sheep anti-(rabbit IgG) antiserum as described above. After addition of the precipitating antiserum the tubes were mixed, incubated (0.5h, room temperature) and centrifuged (3000g, 0.5 h, 4°C) after the addition of 1 ml of poly(ethylene glycol) solution (2.0%, w/v, in 0.05M-phosphate). The soluble free fraction was aspirated to waste and precipitated radioactivity Direct 'two-site' immunoradiometric assay for corticoti was determined in an Innotron Hydragamma 16 counter.
Results and discussion
The highly purified immunoglobulin required for radioiodination was prepared from the two sheep antisera (PS1 and PS2) which were raised against the corticotropin-(l-24)-peptide (Synacthen) conjugate as described above. However, a range of immunoadsorbents were employed, which resulted in preparations with distinct specificities (Fig. 1) ized corticotropin-(l 1-39)-peptide and must therefore be specific for the residue-17-24 region of the molecule. Standard curves prepared by using each of the ' 2'-labelled sheep anti-corticotropin IgG preparations in combination with each of the rabbit anticorticotropin antisera can be seen in Fig. 2 . The curves demonstrated large differences in dose response, which relate to the specificities of labelled and unlabelled antibodies. Thus the standard curve prepared by using labelled sheep antibody PSia and rabbit anti-[corticotropin-(34-39)-peptide] antiserum (Apro) (Fig. 2, El) demonstrated only a 2.7-fold change in bound radioactivity over the range of standards and only 15.10% binding of labelled antibody at a corticotropin concentration of 10OOpg/ml. In contrast, the standard curve prepared by using PSIb and Apro (Fig. 2, * Fig. 2(A) and is characterized by high binding of labelled antibody (51% at 1000 pg of corticotropin/ml) and a large change in bound radioactivity (17.0-fold) across the range of standards. These data suggest that the exclusion of antibodies, directed against determinants which are absent in the intact analyte molecule, from antisera raised to analyte fragments is a necessary prerequisite to establishing 'two-site' i.r.m.a.'s and that this can be achieved by selective immunoadsorption.
The need to minimize the steric inhibition of antibody binding resulting from the use of labelled and unlabelled antibodies which are specific for the same or adjacent immunodeterminants is also illustrated in Fig. 2 . Whereas the standard curve prepared by using the labelled antibody preparation PS2a and rabbit anti-[corticotropin-(34-39)-peptide] antiserum (Apro) (Fig. 2, A) demonstrated high binding (51% at 1000 pg of corticotropin/ml), a second standard curve prepared by using PS2a and the rabbit anti-[corticotropin-(1 7-39)-peptide] . Dose response was assessed at a range of dilutions (1: 500, 1:300 and 1: 100) of the rabbit anti-corticotropin antisera by the addition of reagent mixtures (0.2ml) containing labelled and unlabelled antibodies to corticotropin standards (0.5 ml, 0 and 30pg/ml), followed by overnight incubation and separation of bound and free labelled antibody as described in the text.
(CII) antiserum did not (Fig. 2, 0) . Only 31% of the labelled antibody was bound at 1000pg of corticotropin/ml. The inhibition of binding was in this case probably due to competition between the labelled and unlabelled antibodies for common immunodeterminants on the corticotropin molecule, since the actual specificity of the labelled antibody preparation [PS2a; corticotropin-(17-24)-peptide] is entirely contained within the sequence 17-39 against which the rabbit antiserum was raised (Fig. 1) . It is surprising, therefore, that the inhibition of binding of the labelled antibody was not greater, but this may be due to a predominance of antibodies in the rabbit antiserum which are directed against determinants further towards the C-terminus of corticotropin. Competition between labelled and unlabelled antibodies for binding sites on the analyte molecule was also observed in a standard curve prepared by using the labelled antibody preparation PSIa with the CII antiserum (Fig. 2, A) when compared with a curve prepared by using the same labelled antibody preparation (PS 1 a) and the rabbit anti-[corticotropin-(34-39)-peptide] (Apro) antiserum (Fig. 2, El) . But there was no evidence of competition in standard curves prepared by using the labelled antibody preparation PSI b in combination with either the Apro (Fig. 2, M) or CII (Fig. 2, 0 ) rabbit antisera. This would be expected, since this labelled antibody and these unlabelled antibodies have no immunodeterminants in common. The absence of competition between these antibodies was confirmed by comparing the 'simultaneous addition' standard curves with curves prepared by delaying the addition of rabbit antiserum (results not shown), that is, by preincubating the labelled antibody with corticotropin. Neither the 'delayed addition' standard curve prepared by using Apro rabbit antiserum nor the 'delayed addition' standard curve prepared by using the CII antiserum showed any improvement in dose response over respective 'simultaneous addition' standard curves. In standard curves in which competition was demonstrated, the concentration of rabbit antiserum had a pronounced effect on dose response (Fig. 3b) . In an experiment in which reagent mixtures (0.2 ml) containing 1 251-labelled sheep anti-[corticotropin-(l 7-24)-peptide] IgG (50000c.p.m./200p1; PS2a) and rabbit anti-[corticotropin-(17-39)-peptide] antiserum (CII) at a range of dilutions (1 :500, 1: 300 and 1: 100) in assay buffer were added to corticotropin standards (O and 30pg/ml; 0.5 ml) and incubated overnight (room temperature), a progressive inhibition of dose response was observed with increasing concentrations of rabbit antiserum. This further illustrates the need to avoid the use of labelled and unlabelled antibodies which compete for binding sites on the analyte molecule, since the phenomena must limit the sensitivity of resultant assays. However, the progressive inhibition of dose response with increasing concentration of rabbit antiserum was not observed in a similar experiment (Fig. 3a (1 g/ml) and the plasmas (09:00-11:OOh) of 25 normal volunteers (Fig. 4 ). The sensitivity of the i.r.m.a. (the lowest detectable dose ofcorticotropifi) was 8 pg/ml (4 pg; 95% confidence interval 1.8-6.0) as judged by a 2.5-S.D. increase in duplicate radioactivity counts from counts at zero corticotropin. This compares favourably with detection limits quoted by other investigators for corticdtropin r.i.a.'s employing preliminary extraction of analyte. The normal volunteers (25-65 pg of corticotropin/ml) were clearly delineated from zero and in substantial agreement with other estimates of normal corticotropin levels by r.i.a. (Landon & Greenwood, 1968) and by bioassay (Holdaway et al., 1973) . Data for the calculation of the precision profile were obtained from a standard curve as in Fig. 4 and from the assay of 25 unknown plasmas.
In addition to avoiding competition, the use of labelled and unlabelled antibodies which are directed against opposite ends of the analyte molecule also has the advantage of enabling a substantial increase in assay specificity. Whereas corticotropin fragments may cross-react in the r.i.a., the detection of corticotropin immunoreactivity in the 'two-site' i.r.m.a. for the hormone requires the presence of both the corticotropin 2-16 sequence and, in combination, the corticotropin 34-39 sequence. The N-terminal sequence is required for the binding of the labelled antibody and the Cterminal antibody is required to ensure the precipitation of the bound labelled antibody. Thus only the intact biologically active corticotropin molecule may be measured in this system, and the divergence of results obtained by bioassay and radioimmunoassay in the past (Fleisher et al., 1966) can be overcome. This is also illustrated in Fig. 4 . No cross-reaction of the corticotropin fragments 1-24 and CLIP was observed in the 'twosite' i.r.m.a. at concentrations 1000 times higher than that of the highest corticotropin standard.
A precision profile (Ekins, 1976 ) of the corticotropin i.r.m.a. can be seen in Fig. 5 between 150 and 1000 pg/ml. Furthermore, the precision potential of dose estimates is still less than 7% at 20pg/ml, and this indicates that the assay may be able to distinguish between normal values of the hormone and the subnormal levels which may be encountered in disorders of the hypothalamo-pituitary-adrenal axis. The high precision and wide 'operating range' of the assay results from the use of antibody in excess and because the assay is of the 'simultaneous addition' variety. Thus reagent excess reduces the need for precise pipetting of antibodies, and addition of labelled and unlabelled antibodies as a single reagent mixture increases the convenience of the method by eliminating a second pipetting step and with it a further source of random assay error.
Meaningful estimates of subnormal corticotropin levels using the i.r.m.a. are dependent on the stability of the baseline response. The susceptibility of the assay to non-specific interference was therefore assessed as follows. Two sets of 12 duplicate tubes were labelled. To the first set was added horse serum (0.5ml) treated as described above, and to the second set 12 unknown plasmas (0.5 ml) from individual subjects. The only preparation of plasma samples before assay was mild centrifugation to remove fibrin clots. Baseline response due to plasma constituents and not to endogenous corticotropin was assessed by the addition of a reagent mixture (0.2ml) containing labelled antibody (preparation PSIb) and a rabbit antiserum (1: 500) in assay buffer which was raised not to corticotropin but to prolactin. Corticotropin therefore could not react in this system and variation in the baseline response would be due to interference. The tubes were incubated overnight and the separation of 'bound' and free labelled antibody was achieved by the addition of a sheep anti-(rabbit IgG) precipitating antiserum as described in the text. The mean precipitated radioactivity in the horse serum group was 2649c.p.m. and the coefficient of variation (c.v.) 6.2%. There was no significant difference between the mean for this group and the mean precipitated radioactivity (2599c.p.m.) of the sample plasma group. This indicates that interference in the assay from sample plasma constituents was no greater than from the horse serum base for the standards. Furthermore, the c.v. for the unknown plasma group (6.1%) was similar to that of the horse serum group, indicating that the individual sample plasmas had little influence on the stability of the baseline. It is concluded that sample plasmas are unlikely to interfere in the determination of corticotropin with the i.r.m.a.
In conclusion, we have developed a liquid-phase 'two-site' i.r.m.a. for corticotropin that does not require sample extraction. The assay is simple to perform, requiring only one pipetting to initiate and one to complete. The assay is highly sensitive, precise, has a wide operating range, and may be completed in 24h. These are desirable characteristics for a clinical corticotropin assay.
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